ストックスクリーナーアプリを入手
7.38
1.37%
0.10
アフターアワーズ：
7.40
0.02
+0.27%
前日終値:
$7.28
開ける：
$7.33
24時間の取引高:
1.48M
Relative Volume:
1.17
時価総額：
$299.90M
収益：
$128.29M
当期純損益:
$-30.69M
株価収益率:
-9.00
EPS:
-0.82
ネットキャッシュフロー:
$-27.17M
1週間 パフォーマンス:
-12.77%
1か月 パフォーマンス:
-45.33%
6か月 パフォーマンス:
-75.72%
1年 パフォーマンス:
-84.37%
1日の値動き範囲:
$7.21
$7.42
1週間の範囲:
$7.162
$8.497
52週間の値動き範囲:
$6.32
$58.23
Rxsight Inc Stock (RXST) Company Profile
RXST を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RXST
Rxsight Inc
|
7.38 | 343.79M | 128.29M | -30.69M | -27.17M | -0.82 |
|
ABT
Abbott Laboratories
|
120.51 | 232.44B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.65 | 153.66B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
388.90 | 150.87B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
89.53 | 114.55B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.18 | 46.22B | 5.54B | 4.18B | 623.10M | 7.00 |
Rxsight Inc Stock (RXST) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-10 | ダウングレード | Jefferies | Buy → Hold |
| 2025-07-09 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-07-09 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-07-09 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-05-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-04-15 | 開始されました | Piper Sandler | Neutral |
| 2025-04-09 | ダウングレード | UBS | Buy → Neutral |
| 2025-04-04 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2025-04-03 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-12-20 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-11 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-06 | 開始されました | UBS | Buy |
| 2024-10-29 | 開始されました | Jefferies | Buy |
| 2024-08-20 | 繰り返されました | Needham | Buy |
| 2024-08-06 | 繰り返されました | Needham | Buy |
| 2024-05-07 | 繰り返されました | BTIG Research | Buy |
| 2023-12-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-12 | 開始されました | Stifel | Buy |
| 2023-12-04 | 開始されました | Morgan Stanley | Overweight |
| 2023-04-13 | 開始されました | Oppenheimer | Outperform |
| 2022-12-12 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-04-08 | 開始されました | Needham | Buy |
すべてを表示
Rxsight Inc (RXST) 最新ニュース
RxSight's (RXST) Deteriorating Fundamentals and Regulatory Risks: A Cautionary Tale for Investors - AInvest
RXST BREAKING NEWS: BFA Law is Investigating RxSight, Inc. for Securities Fraud; Contact the Firm about how to Potentially Recover Investment Losses - The Globe and Mail
RxSight Downgraded After Q2 Revenue Miss, FY23 Guidance Cut. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc.RXST - PR Newswire
RxSight's Plunge: Securities Fraud Allegations and the Uncertain Future for RXST Shareholders - AInvest
Investigation Continues: RxSight Investors Urged to Contact Glancy Prongay & Murray LLP - AInvest
Securities Fraud Investigation Into RxSight, Inc. (RXST) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm - The Globe and Mail
RxSight, Inc. (RXST) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - The Globe and Mail
RXSIGHT ALERT: Bragar Eagel & Squire, P.C.Announces - GlobeNewswire
Robbins LLP is Investigating the Officers and Directors of - GlobeNewswire
Robbins LLP is Investigating the Officers and Directors of RxSight, Inc. (RXST) to Determine if They Breached Fiduciary Duties Owed to Shareholders - TradingView
Robbins LLP is Investigating the Officers and Directors of RxSight, Inc. (RXST) to Determine if They Breached Fiduciary Duties Owed to Shareholders - GlobeNewswire Inc.
Steris, Solventum stocks upgraded at Morgan Stanley (STE:NYSE) - Seeking Alpha
RxSight stock rating downgraded by Morgan Stanley on growth concerns - Investing.com Canada
Morgan Stanley Downgrades RxSight Inc. (RXST) to Equalweight - StreetInsider
What makes RxSight Inc. stock price move sharplyFree Stock Market Expert Consultation - beatles.ru
Top 3 Health Care Stocks That Could Blast Off In July - Benzinga
RxSight, Inc. (RXST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - MSN
The Biotech Bubble: RxSight's Downfall and the Dangers of Overvalued Innovation - AInvest
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Stockholders to Connect - ACCESS Newswire
INVESTOR ALERT: Investigation of RxSight, Inc. (RXST) Announced by Holzer & Holzer, LLC - GlobeNewswire
Securities Fraud Investigation Into RxSight, Inc. (RXST) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm - The Globe and Mail
Midday Stock Roundup: Karman Holdings Up Nearly 3% - Orange County Business Journal
Johnson Fistel Begins Investigation on Behalf of RxSight, Inc. (RXST) Shareholders - GlobeNewswire
RxSight and iRobot: Navigating Legal Risks and Financial Declines in Healthcare and Tech - AInvest
Robbins LLP Informs RxSight, Inc. Stockholders that it is Investigating the Officers and Directors of RXST to Determine if They Breached Fiduciary Duties Owed to Shareholders - ACCESS Newswire
RxSight stock falls after Wells, BTIG downgrade on poor results - MSN
RxSight’s 5% Spike: A Technical Rally or Isolated Momentum Play? - AInvest
Securities Fraud Investigation Into RxSight, Inc. (RXST) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The Globe and Mail
RxSight, Inc. Securities Lawsuit Investigation - Claim Depot
RxSight’s 5% Spike: Technical Oversold Triggers and Mixed Peer Signals - AInvest
RxSight's Mysterious 6.7% Spike: Technical Clues Uncovered - AInvest
RxSight Plummets 38%—What’s Driving This Historic Drop? ⚠️ - AInvest
Is RXST's Q4 2024 EPS decline a concern? - AInvest
What's the outlook for RXST's EPS in 2025? - AInvest
Jefferies Downgrades RxSight to Hold From Buy, Adjusts Price Target to $9 From $24 - MarketScreener
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Gain Therapeutics (GANX) and Edwards Lifesciences (EW) - The Globe and Mail
Jefferies downgrades RxSight stock rating to Hold on elongated selling cycles By Investing.com - Investing.com South Africa
Jefferies downgrades RxSight stock rating to Hold on elongated selling cycles - Investing.com Nigeria
Jefferies Downgrades RxSight Inc. (RXST) to Hold - StreetInsider
RxSight(RXST) Plunges 37.84% on Lowered Revenue Outlook - AInvest
RxSight's Revised Guidance Reflects Deeper Market Shifts (Rating Downgrade) (NASDAQ:RXST) - Seeking Alpha
RxSight stock slides on lower Q2 revenue guidance - MSN
Crude Oil Moves Higher; RxSight Shares Plunge - Benzinga
RxSight Stock Drops 50% Following Disappointing Q2 ResultsNews and Statistics - IndexBox
Needham maintains Buy rating on RxSight stock despite near-term concerns - Investing.com Australia
Why Did RxSight Plunge 49.27%? Revenue Forecast Cut - AInvest
RxSight Stock Sinks 50% as Medical Device Maker Slashes Revenue Outlook - Investopedia
RxSight stock rating downgraded to Neutral by BTIG amid sales challenges - Investing.com Australia
Aehr Test Systems Posts Downbeat Sales, Joins RxSight, Vertical Aerospace And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - 富途牛牛
RxSight’s preliminary Q2 2025 revenue expected to decrease 4% - Medical Buyer
Rxsight Inc (RXST) 財務データ
収益
当期純利益
現金流量
EPS
1.67%
0.94%
大文字化:
|
ボリューム (24 時間):